Analysis: Erbitux to top head/neck cancer
14th Nov 2006, 01:52 GMT
Erbitux, made jointly by ImClone, Bristol-Myers Squibb and Merck KGaA, will become the market leader for squamous cell carcinoma of the head and neck by ...
Analysis: Erbitux to top head/neck cancer related news:
- Adams hurts neck — NFL Player News : CBS SportsLine.com
- Ryk's neck injury 'not serious' — News24
- Young gymnast who broke his neck could receive £6m — TimesOnline: Britain
- Minnesota skates to a pair of ties with St. Cloud State (CSTV U-WIRE) — Yahoo! Sports - NCAA Hockey News
- Dutch election news - Part II — Expatica Netherlands: Dutch news in English.
- Blackhawks' Bourque out with neck cut — CBC | Hockey News
- Recount starts in SW Florida race — floridatoday.com - BreakingNews
- Blackhawks' Bourque out 3-6 weeks after neck surgery — ESPN.com - NHL
- Bourque could miss 6 weeks after neck surgery — FOXSports.com News for NHL
- Risk after colon cancer higher for the very fat and very thin — EurekAlert! - Breaking News
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Neurogen's obesity drug in phase 1 trial
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries